Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07521475 · ClinicalTrials.gov registry record · NA
Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
A NA study, sponsored by Insulet Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 350
- Enrollment target
NCT07521475 is a NA study that is actively recruiting participants, run by Insulet Corporation. The registered enrollment target is 350 participants.
The verdict
NCT07521475, a NA study, is actively recruiting participants, sponsored by Insulet Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
Study Summary
A multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults with type 2 diabetes using basal/bolus insulin therapy or basal-only insulin therapy, with the primary endpoint after 15 weeks and secondary analysis at 26 weeks; followed by an extension phase after completion of the 26-week trial where the Intervention group will continue to use Omnipod M and the Control group will crossover to use Omnipod M for 26 weeks
Interventions
- DEVICE Device: Omnipod M System with study CGM
- DEVICE Standard Therapy plus study CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2026-04-30 |
| Est. Completion | 2027-09-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07521475
The ClinicalTrials.gov registry entry for NCT07521475 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insulet Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Device: Omnipod M System with study CGM is the first listed.
NCT07521475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07521475 about?
NCT07521475 is a clinical study titled "Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes". A multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults with type 2 diabetes using basal/bolus insulin therapy or basal-only insulin therapy, with the primary endpoint after 15 weeks and secondary analysis at 2...
What is the current status of trial NCT07521475?
This trial is currently recruiting. It is a NA study. The enrollment target is 350 participants. The study started on 2026-04-30. Estimated completion is 2027-09-23.
What interventions are being tested in trial NCT07521475?
The interventions under investigation include: Device: Omnipod M System with study CGM (DEVICE), Standard Therapy plus study CGM (DEVICE).
Who is sponsoring clinical trial NCT07521475?
This trial is sponsored by Insulet Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.